Karen R. Jacobson, MD, MPH

Assistant Professor, Medicine

Karen Jacobson

Biography

Dr. Karen Jacobson is an Assistant Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of drug resistant tuberculosis, including identification of social, biological, and economic determinants of and risk factors for drug resistance and approaches for improving TB outcomes in resource-limited settings. Dr. Jacobson has established a highly productive collaboration with researchers at Stellenbosch University in Cape Town, South Africa, investigating the drivers of drug resistance in the Western Cape Province of South Africa and working to identify potentially modifiable factors.

Other Positions

  • Assistant Professor, Epidemiology, Boston University School of Public Health

Education

  • Johns Hopkins University School of Medicine, MD
  • Harvard School of Public Health, MPH
  • Yale University, BS

Publications

  • Published on 3/1/2019

    Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 Mar 01; 23(3):358-362. PMID: 30940300.

    Read at: PubMed
  • Published on 2/13/2019

    Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clin Infect Dis. 2019 Feb 13. PMID: 30759187.

    Read at: PubMed
  • Published on 11/1/2018

    Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr. 2018 Nov 01; 79(3):407-411. PMID: 30063648.

    Read at: PubMed
  • Published on 9/29/2018

    Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, Parry CDH, Horsburgh CR, Warren RM, Jacobson KR. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis. 2018 Sep 29; 18(1):488. PMID: 30268101.

    Read at: PubMed
  • Published on 8/21/2018

    McIntosh AI, Jenkins HE, White LF, Barnard M, Thomson DR, Dolby T, Simpson J, Streicher EM, Kleinman MB, Ragan EJ, van Helden PD, Murray MB, Warren RM, Jacobson KR. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis. PLoS Med. 2018 08; 15(8):e1002638. PMID: 30130377.

    Read at: PubMed
  • Published on 8/1/2018

    Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia? Int J Tuberc Lung Dis. 2018 08 01; 22(8):358-362. PMID: 29991400.

    Read at: PubMed
  • Published on 7/13/2018

    Geadas C, Acuna-Villaorduna C, Mercier G, Kleinman MB, Horsburgh CR, Ellner JJ, Jacobson KR. FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective study. BMC Res Notes. 2018 Jul 13; 11(1):464. PMID: 30001743.

    Read at: PubMed
  • Published on 4/1/2018

    Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018 04; 6(4):265-275. PMID: 29595509.

    Read at: PubMed
  • Published on 4/1/2018

    Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):405-412. PMID: 29239900.

    Read at: PubMed
  • Published on 2/19/2018

    Brooks-Pollock E, Jacobson KR. Rethinking tuberculosis control by targeting previously treated individuals. Lancet Glob Health. 2018 04; 6(4):e361-e362. PMID: 29472017.

    Read at: PubMed

View 17 more publications: View full profile at BUMC

View all profiles